. 2015 Oct 7;6(34):36081–36097. doi: 10.18632/oncotarget.5555

Table 4. Summary risk estimates of the association between dietary Saturated, monounsaturated, and polyunsaturated fatty acid intake and endometrial cancer risk, dose-response analysis (per 10 g/day increment).

	Saturated fatty acid					Monounsaturated fatty acid					Polyunsaturated fatty acid
	No. of study	Summary RR (95%CI)	I² value (%)	P_h^*	P_h^**	No. of study	Summary RR (95% CI)	I² value (%)	P_h^*	P_h^**	No. of study	Summary RR (95% CI)	I² value (%)	P_h^*	P_h^**
Overall	13	1.02 (0.97–1.08)	66.0	< 0.01		9	0.98 (0.96–1.001)	0	0.68		8	1.00 (0.95–1.06)	0	0.46
Study design					0.17					0.87					0.62
Cohort study	3	0.97 (0.93–1.00)	15.3	0.31		3	0.97 (0.94–1.00)	0	0.87		2	1.00 (0.86–1.16)	54.0	0.14
Case-control study	10	1.06 (0.98–1.14)	62.3	< 0.01		6	0.98 (0.95–1.01)	0	0.47		7	1.02 (0.94–1.09)	0	0.51
Quality scores					0.81					0.49					0.80
High (≥9)	8	1.02 (0.96–1.07)	66.6	< 0.01		7	0.98 (0.96–1.01)	0	0.92		5	1.00 (0.94–1.07)	0	0.55
Low (<9)	5	1.04 (0.90–1.20)	70.9	< 0.01		3	1.00 (0.89–1.11)	41.8	0.18		3	1.05 (0.82–1.36)	44.2	0.17
Geographic location					0.66					0.36					0.28
North America	10	1.04 (0.97–1.12)	69.1	0.05		6	0.99 (0.96–1.03)	0	0.68		5	1.05 (0.94–1.16)	12.7	0.33
Europe	3	1.00 (0.93–1.09)	67.8	< 0.01		3	0.97 (0.94–1.00)	0	0.45		3	0.98 (0.90–1.05)	0	0.69
Validated FFQ					0.28					0.20					0.93
Yes	9	1.00 (0.96–1.05)	48.9	0.05		8	0.99 (0.96–1.01)	0	0.81		7	1.00 (0.94–1.08)	10.6	0.35
No	4	1.12 (0.90–1.38)	83.3	< 0.01		1	0.95 (0.91–1.00)	N/A	N/A		1	1.01 (0.88–1.17)	N/A	N/A
Number of cases					0.22					0.17					0.97
≥ 450	7	1.05 (0.99–1.12)	64.2	0.01		6	0.99 (0.96–1.02)	0	0.66		5	1.00 (0.94–1.07)	0	0.61
< 450	6	0.98 (0.89–1.07)	58.5	0.03		3	0.95 (0.91–0.99)	0	0.95		3	1.03 (0.78–1.36)	50.2	0.13
Energy-adjusted model					0.99					0.35					0.64
Yes	7	1.02 (0.96–1.10)	71.8	< 0.01		6	0.99 (0.95–1.01)	0	0.95		4	1.00 (0.90–1.11)	42.4	0.16
No	6	1.03 (0.94–1.13)	64.0	0.02		3	0.98 (0.89–1.07)	43.5	0.17		4	1.03 (0.93–1.13)	0	0.74
Adjustment for potential confounders
Total energy intake					0.41					0.20					0.93
Yes	12	1.03 (0.98–1.09)	67.5	< 0.01		8	0.99 (0.96–1.01)	0	0.81		7	1.00 (0.94–1.08)	10.6	0.35
No	1	0.94 (0.85–1.04)	N/A	N/A		1	0.95 (0.91–1.00)	N/A	N/A		1	1.01 (0.88–1.17)	N/A	N/A
Body mass index					0.41					0.20					0.93
Yes	12	1.03 (0.98–1.09)	67.5	< 0.01		8	0.99 (0.96–1.01)	0	0.81		7	1.00 (0.94–1.08)	10.6	0.35
No	1	0.94 (0.85–1.04)	N/A	N/A		1	0.95 (0.91–1.00)	N/A	N/A		1	1.01 (0.88–1.17)	N/A	N/A
Cigarette smoking					0.62					0.48					0.83
Yes	10	1.03 (0.97–1.10)	68.8	< 0.01		6	0.99 (0.96–1.01)	0	0.62		5	1.00 (0.93–1.07)	0	0.55
No	3	1.00 (0.88–1.13)	67.3	0.05		3	0.97 (0.93–1.01)	0	0.45		3	1.03 (0.87–1.21)	44.5	0.17
Parity					0.57					0.20					0.93
Yes	11	1.02 (0.97–1.07)	59.0	0.01		8	0.99 (0.96–1.01)	0	0.81		7	1.00 (0.94–1.08)	10.6	0.35
No	2	1.13 (0.77–1.64)	90.7	< 0.01		1	0.95 (0.91–1.00)	N/A	N/A		1	1.01 (0.88–1.17)	N/A	N/A
Oral contraceptive use					0.71					0.43					0.80
Yes	10	1.03 (0.97–1.09)	69.6	< 0.01		6	0.98 (0.96–1.01)	0	0.91		5	1.00 (0.94–1.07)	0	0.55
No	3	1.00 (0.86–1.17)	64.7	0.06		3	1.00 (0.89–1.11)	41.8	0.18		4	1.05 (0.82–1.36)	44.2	0.17
HRT use					0.25					0.21					0.75
Yes	11	1.04 (0.98–1.10)	69.8	< 0.01		7	0.99 (0.96–1.01)	0	0.72		6	1.00 (0.94–1.07)	0	0.69
No	2	0.93 (0.85–1.03)	0	0.75		2	0.95 (0.91–1.00)	0	0.83		2	1.53 (0.52–4.46)	71.7	0.06

CI, confidence interval; FFQ, food frequency questionnaire; N/A, not available; RR, relative risk.

P-value for heterogeneity within each subgroup.

^**

P-value for heterogeneity between subgroups with meta-regression analysis.